The purpose of the screening is to detect and treat breast cancer cases earlier, and thus to achieve benefits for the patients through less radical treatment and prolonged life, as well as a reduction in effort and costs in the health care system (de Koning et al., 1992). It is difficult to obtain an unbiased estimate of the prolonged life of the individual patient, and breast cancer mortality is therefore used as the most important measure of benefit for the patients. Day et al. (1989) emphasise the need to monitor the outcome of programmes to ensure that the aims of the programme are actually achieved.
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The first population-based mammographic screening programme started in the municipality of Copenhagen in April, 1991. All women in the municipality aged 50-69 years are invited every second year to a screenig mammography. The programme comprses approximately 44,000 women, which is 8.3% of the total female population in this age group in Denmark. In 1993-94, at least three more of the 16 regions will start screening programmes. The purpose of the screening is to detect and treat breast cancer cases earlier, and thus to achieve benefits for the patients through less radical treatment and prolonged life, as well as a reduction in effort and costs in the health care system (de Koning et al., 1992) . It is difficult to obtain an unbiased estimate of the prolonged life of the individual patient, and breast cancer mortality is therefore used as the most important measure of benefit for the patients. Day et al. (1989) emphasise the need to monitor the outcome of programmes to ensure that the aims of the programme are actually achieved.
The screening programme in Copenhagen is offered to all women aged 50-69 years, and no internal comparison group is thus available. One of the possibilites in this situation is to use regions without screening programmes as the control group. For such an evaluation to be valid it is necessary to assume that any changes in the breast cancer mortality would have been similar in the screening and the non-scrning regions, provided no screening was introduced. The present study attempts to check this assumption by using data collected in the Danish population and diease resters. The paper desibes the breast cancer incidence and mortality in Denmark during the 20 year period, 1970-89, before the first screening programme was started, and it discusses the possibility of using a regional comparison group for evalating the potential reduction in breast cancer mortality. Data al., 1992) . A total of 49,174 cases were identified from the ICD-7 codes 170. The data were tabulated by 5 year age groups (0-4, 5-9, ..., 85 +) 5 year calendar periods (1970-74, 1975-79, 1980-84, 1985-89) and the 16 regions (Copenhagen municipality, Frederiksberg municipality and the ICD-8 code 174 with breast cancer as the underlying cause of death. The deaths were tabulated in the same way as the incident cases. Table I shows the incident cases and  deaths by age group and period. Data on the female population during the period 1970-89 were retrieved from the files of the National Bureau of Statistics (Danmarks Statistik, 1990) . These data were used to calculate the number of years lived at risk.
Analysis
The study of the geographical differences in incidence and mortality was separated into two analyses using equivalent multiplicative Poisson models (Breslow & Day, 1987, pp. 119-176 (Payne et al., 1987) was used to fit the models. log 1g,, =-L + aE + E + t + C, The age*time effect is shown in Figure 2 , in which the incidence in the period 1970-74 is equal to 1 in each age group. The incidence in younger women (age 30-59) increases steadily, reaching almost 40% dunng the study period. lthis is combined with a smaller increase of 10-30% in incidence in elderly women (age 60-79), turning to a decrease of about 10% in the oldest age group (age 80-84).
Using the Copenhagen municipality as the standard, the geographical variation varies from 17% below the standard in Viborg county to 6% above the standard in Frederisksborg county (Table III) .
When the analysis was restricted to the age group 50-69 years, all the two-factor interactions could be excluded and the incidence data for this age group could consequently be described by the model: (Table II) . The mortality data can therefore be described by the model: log 1,, = A + aC. + O, + (XI The main effects can be described as follows: mortality increases with increasing age, and overall has increased with time by 8%, the significant change occurring between the two last periods (Figure 3) . Finally, still using the Copenhagen municipality as the standard, there is a variation in mortality from 20% below the standard in Sonderjylland county to 3% above in Frederiksberg municipality (Table III) .
When the analysis was restricted to the age group 50-69 years, the interaction between age and region showed a Pvalue of 0.005, and the mortality data in this age group can consequently best be described by the following model:
log A,,= AL + a, + a,+ a, + M, (Storm, 1984 1975-79; *, 1980-84; 1985-89. 1970-74 1975-79 1980-84 1985-89 Fugwe 3 Trends of breast cancer mortality with confidence interval. Fitted in the model: log A= +ca,+nF+a, (1970-74= 1) . (Copenhagen munipality = 1). Figure 4 ). The present study shows that the contribution to this increase in the age-standardised rate comes from all age groups below 80 years, although the contribution decreases with increasing age (see Figure 2) . The age-standardised breast cancer mortality was, however, stable up until the late 1980s. A major increase in the incidence is expected to be followed by an increase in the mortality unless an essential improvement in treatment is achieved or a large proportion of the extra incident cases are non-fatal. Systematic trials of adjuvant systemic treatment of breast cancers have been conducted on a national basis in Denmark since 1977. These trials have shown a reduction in the overall mortality in premenopausal women after 8-9 years of follow-up of 20% after treatment with cyclophosphamide and of 30% with cyclophosphamide + methotrexate + 5-fluorouracil (CMF). A reduction of 16% has been found in post-menopausal women below the age of 70 treated with tamoxifen (Fischerman & Mouridsen, 1988) .
No systematic attempt to achieve early diagnosis of breast years after the incidence started to increase.
Regional differences are present in both the incidence of and mortality from breast cancer in Denmark, the rates being highest in urban areas (Carstensen & Jensen, 1986) . Furthermore, this study shows that these regional differences have remained fairly stable over the last 20 years, thus it seems reasonable to exclude the interaction between region and time from the models. Ongoing diagnostic mammography seems to be evenly distnrbuted across counties. In 1990, more than 80% of the diagnostic mammograms were taken in women aged 30-69 years. The number of mammograms taken in Copenhagen, Arhus and Nordjylland was, respectively, equivalent to 5%, 4% and 4% of the number of women in this age group. As the mammography clinics in Copenhagen to some extent also recruit women living outside the municipality, these data indicate an even distribution across counties (A.H. Andreasen et al., unpublished data). The effect of a population-based mammographic screening programme must be evaluated from the difference between the observed mortality from breast cancer and the expected mortality predicted under the assumption that screemng was not implemented. This prediction must be based on the mortality in a comparison group, and Day et al. (1989) 1940 1945 1950 1955 1960 19651970 1975 1980 1985 1990 Figwe 4 Breast cancer incidence (0) The use of a historical comparison group, i.e. breast cancer mortality in Copenhagen in the prescreening period, seems problematic as it is based on the assumption either that the time can be eliminated or that the time trend can be modelled. Breast cancer mortality changed considerably immediately before the start of the Copenhagen screening programme (see Figure 2 ) and the time trend would therefore be difficult to model. About 70% of the invited women participated in the first round of the Copenhagen screening programme (K.P. Olesen, personal observation, 1993) , but a comparison between the screened and unscreened women could be affected by a severe selection bias, as the screened group will probably include the most health-conscious and presumably most healthy women, as seen in the Malm0 study (Gullberg et al., 1991) .
It is possible that a nationwide screening programme will start in Denmark at some time in the future, but it is not likely to happen before the crucial 7-10 years after the start of the Copenhagen screening programme in 1991. It will therefore be possible during this period to identify a comparison group from an area where screening has not been offered.
A geographical comparison group has been used in two previous studies. In the Breast Cancer Detection and Demonstration Project (BCDDP) (Morrison et al., 1988) , the expected mortality for the screened group was calculated based on the age-specific incidence and case fatality rates found in the ten regions included in the surveillance, epidemiology and end results (SEER) data of Young et al. (1981) . In the UK Trial on Early Detection of Breast Cancer (UK Trial EDBC, 1988) , the expected number of breast cancer deaths in the screening regions was calculated based on the mortality rates in neighbouring regions. To correct for geographical differences not due to screening, the expected number of deaths in the screening regions was furthermore multiplied by the standardised mortality ratio (SMR) for the neighbouring regions in the 7 years preceding the start of screening.
In the BCDDP study it was thus assumed that the screened population, apart from the screening, was comparable with the population in the SEER regions. A similar assumption would not be reasonable for Denmark, as our analysis showed that the regional effect could not be eliminated from the model. By multiplying by the SMR for the prescreening period in the UK trial, it was assumed only that the breast cancer mortality trends were similar in the screening and neighbouring regions. As (1989) .
In our analysis, the interaction between region and time is the crucial term for the validity of using the regional comparison group in the evaluation of the Copenhagen screening (Anonymous, 1993) . The methodological reservations listed above further emphasise the need to be cautious. Our study thus underlines the difficulties inherent in the evaluation of the outcome of screening programmes without internal control groups.
